These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis. Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954 [TBL] [Abstract][Full Text] [Related]
7. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma. Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783 [TBL] [Abstract][Full Text] [Related]
8. Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial. Mauge L; Mejean A; Fournier L; Pereira H; Etienne-Grimaldi MC; Levionnois E; Caty A; Abadie-Lacourtoisie S; Culine S; Le Moulec S; Linassier C; Théodore C; Ravaud A; Albiges L; Grine A; Tartour E; Milano G; Gille AS; Verkarre V; Helley D; Oudard S; Clin Cancer Res; 2018 Nov; 24(22):5534-5542. PubMed ID: 30061359 [No Abstract] [Full Text] [Related]
9. Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response. Kovacova J; Juracek J; Poprach A; Buchler T; Kopecky J; Fiala O; Svoboda M; Slaby O Anticancer Res; 2018 May; 38(5):2961-2965. PubMed ID: 29715124 [TBL] [Abstract][Full Text] [Related]
10. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy. Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203 [TBL] [Abstract][Full Text] [Related]
11. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979 [TBL] [Abstract][Full Text] [Related]
12. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic. Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708 [TBL] [Abstract][Full Text] [Related]
13. A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy. Kim SH; Kim S; Joo J; Seo HK; Joung JY; Lee KH; Chung J BMC Cancer; 2016 Aug; 16():577. PubMed ID: 27484254 [TBL] [Abstract][Full Text] [Related]
14. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. Iacovelli R; Lanoy E; Albiges L; Escudier B BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948 [TBL] [Abstract][Full Text] [Related]
15. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience. Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028 [TBL] [Abstract][Full Text] [Related]
16. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis. Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044 [TBL] [Abstract][Full Text] [Related]
17. Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancer. Pompas-Veganzones N; Sandonis V; Perez-Lanzac A; Beltran M; Beardo P; Juárez A; Vazquez F; Cozar JM; Alvarez-Ossorio JL; Sanchez-Carbayo M Tumour Biol; 2016 Oct; 37(10):14301-14310. PubMed ID: 27592258 [TBL] [Abstract][Full Text] [Related]
18. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Al-Marrawi MY; Rini BI; Harshman LC; Bjarnason G; Wood L; Vaishampayan U; MacKenzie M; Knox JJ; Agarwal N; Al-Harbi H; Kollmannsberger C; Tan MH; Rha SY; Donskov FN; North S; Choueiri TK; Heng DY; Target Oncol; 2013 Sep; 8(3):203-209. PubMed ID: 23300029 [TBL] [Abstract][Full Text] [Related]
19. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453 [TBL] [Abstract][Full Text] [Related]
20. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Grünwald V; Lin X; Kalanovic D; Simantov R Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]